Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theratechnologies (THTX)
:THTX
Holding THTX?
Track your performance easily
THTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.08 - $2.18
Previous CloseN/A
Volume43.44K
Average Volume (3M)161.74K
Market Cap
$79.03M
Enterprise Value$110.99M
Total Cash (Recent Filing)$5.73M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Feb 20, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding45,980,020
10 Day Avg. Volume159,900
30 Day Avg. Volume161,741
Standard Deviation0.28
R-Squared0.06
Alpha-0.00990
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.05
Price to Cash Flow (P/CF)4.80
P/FCF Ratio3.40
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue0.90
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda2.37
Forecast
1Y Price Target
$3.80Price Target Upside119.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Theratechnologies News
PremiumCompany Announcements
Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV®
PremiumCompany Announcements
Theratechnologies Seeks FDA Approval for EGRIFTA SV® Changes
PremiumCompany Announcements
Theratechnologies Secures Canadian Rights for Ionis RNA Medicines
PremiumCompany Announcements
Theratechnologies Awaits FDA Decision on Tesamorelin F8Bulls Say, Bears Say
Bulls Say
Financial Performance2Q24 total revenue of $22M from sales of EGRIFTA SV and TROGARZO exceeded our estimate of $19.52M and consensus of $21.73M.
ProfitabilityTHTX reports a positive net income for the first time, marking the beginning of sustainable profitability for the company.
Revenue GrowthEGRIFTA SV remains the key revenue driver, demonstrating a 26.6% year-over-year increase.
Bears Say
Competitive PressuresTROGARZO sales decreased 22.9% year-over-year due to a loss of market share secondary to competitive pressures.
Operational ChallengesThe stock is facing near-term headwinds until the full impact of the manufacturing pause on the key revenue driving asset EGRIFTA SV is confirmed.
Supply Chain RisksThere is a risk of a temporary supply disruption for EGRIFTA SV due to an unexpected voluntary shutdown of the contract manufacturer's facility following an FDA inspection.
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
25.16% Other Institutional Investors
74.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
THTX FAQ
What was Theratechnologies’s price range in the past 12 months?
Theratechnologies lowest stock price was $1.08 and its highest was $2.18 in the past 12 months.
What is Theratechnologies’s market cap?
Theratechnologies’s market cap is $79.03M.
When is Theratechnologies’s upcoming earnings report date?
Theratechnologies’s upcoming earnings report date is Feb 20, 2025 which is in 33 days.
How were Theratechnologies’s earnings last quarter?
Theratechnologies released its earnings results on Oct 10, 2024. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03.
Is Theratechnologies overvalued?
According to Wall Street analysts Theratechnologies’s price is currently Undervalued.
Does Theratechnologies pay dividends?
Theratechnologies does not currently pay dividends.
What is Theratechnologies’s EPS estimate?
Theratechnologies’s EPS estimate is 0.05.
How many shares outstanding does Theratechnologies have?
Theratechnologies has 45,980,020 shares outstanding.
What happened to Theratechnologies’s price movement after its last earnings report?
Theratechnologies reported an EPS of $0.06 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went up 3.279%.
Which hedge fund is a major shareholder of Theratechnologies?
Currently, no hedge funds are holding shares in THTX
---
Theratechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.80 (119.65% Upside)
$3.80 (119.65% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.0%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.98%
Trailing 12-Months
Company Description
Theratechnologies
Theratechnologies, Inc. is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies was founded on October 19, 1993 and is headquartered in Montreal, Canada.
---
THTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive financial performance and growth for EGRIFTA SV, alongside challenges related to supply chain issues and declining sales for Trogarzo. Despite the supply disruptions, the company remains optimistic about its profitability and strategic direction.Read More>---
THTX Stock 12 Month Forecast
Average Price Target
$3.80
▲(119.65% Upside)
Technical Analysis
Evolus
―
Karyopharm Therapeutics
―
Chimerix
―
Moleculin Biotech
―
Aclaris Therapeutics
―
Amicus
―
Best Analysts Covering THTX
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+4.77%
upgraded a buy rating 3 months ago
Copying Andre Uddin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.77% per trade.
---